Abstract:Xiaohui Bian, 1– 3, &ast Jining He, 1– 3, &ast Rui Zhang, 1– 3 Sheng Yuan, 1– 3 Kefei Dou 1– 4 1 Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 3 State Key Laboratory of Cardiovascular Disease, Beijing, People's Republic of China; 4 National Clinical Research Center for Cardiovascular Diseases, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Kefei Dou, Cardiometabolic Medicine Center, National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, A 167 Beilishi Road, Xicheng District, Beijing, 100037, People's Republic of China, Tel +86-13801032912, Fax +86-10-6831-3012, Email Background: Chronic low-grade inflammation is the common mechanism of both atherosclerosis and type 2 diabetes mellitus (T2DM), and systemic immune-inflammation index (SII) has been emerged as a novel and simple inflammatory biomarker. However, the association between SII and glycemic metabolism and their synergetic effect on the prognosis of coronary artery disease (CAD) patients remains unclear. Methods: A total of 8602 patients hospitalized for percutaneous coronary intervention (PCI) were included. The primary endpoint was major adverse cardiovascular events (MACE), including all-cause death, myocardial infarction (MI), and target vessel revascularization. According to the optimal cut-off value of SII for MACEs, patients were grouped into higher levels of SII (SII-H) and lower levels of SII (SII-L) and further divided by the concomitance of T2DM into four groups: SII-H/T2DM, SII-H/Non-T2DM, SII-L/T2DM, SII-L/Non-T2DM. Results: During a median 2.4-year follow-up, 522 MACEs occurred. The optimal cut-off value of SII for MACEs was 502.5. A 1-unit increase of SII (transformed by natural logarithm) was associated with a 29% increase of MACE risks in the T2DM cohort [adjusted hazard ratio (HR): 1.29, 95% confidence interval (CI): 1.03 to 1.61, P = 0.024], while had no effect in the non-T2DM cohort (HR: 1.03, 95% CI: 0.80 to 1.34, P = 0.800). Compared to those in SII-H/T2DM group, patients in SII-H/Non-T2DM, SII-L/T2DM, SII-L/Non-T2DM had significantly decreased risk of MACEs [adjusted HR: 0.77, 95% CI: 0.61 to 0.98, P = 0.036; adjusted HR: 0.66, 95% CI: 0.50 to 0.87, P = 0.003; adjusted HR: 0.58, 95% CI: 0.45 to 0.74, P < 0.001; respectively]. Multivariable Cox regression analysis also indicated the highest risk in T2DM patients with higher levels of SII than others (P for trend < 0.001). Conclusion: In this large-scale real-world study, diabetic patients with elevated SII levels were associated with worse clinical outcomes after PCI. Keywords: systemic immune-inflammation index, type 2 diabetes mellitus, coronary artery disease, percutaneous coronary intervention Atherosclerosis is identified as a chronic, low-grade inflammatory condition accompanied by autoimmune responses involving both the innate and adaptive immune systems. 1,2 Numerous observational studies have probed the prognostic value of inflammatory biomarkers in patients with coronary artery disease (CAD), 3,4 and several anti-inflammatory clinical trials have further confirmed the causal relationship between inflammation and CAD. 2 The growth of atherosclerotic lesion is characterized by an imbalance between inflammation and its resolving, with various types of blood cells playing distinct roles in this intricate pathological process. 5 A previous study has indicated that elevated neutrophil-to-lymphocyte ratio (NLR) was associated with adverse prognosis for CAD patients, especially in those with type 2 diabetes mellitus (T2DM). 6 Recent research has also highlighted the involvement of platelets in the recruitment and activation of leukocytes and mediate leukocyte-endothelium adhesion, which play a crucial role in the progression of atherosclerosis. 7,8 The uncontrolled and excessive activation of leukocytes and platelets generates a vicious circle, resulting in plaque instability and vessel occlusion. 9 Therefore, both leukocytes and platelets significantly contribute to the initiation and progression of CAD. -Abstract Truncated-

Increased PD-1 on CD4+CD28- T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases

Insulin-Attenuated Inflammatory Response of Dendritic Cells in Diabetes by Regulating RAGE-PKCβ1-IRS1-NF-κB Signal Pathway: A Study on the Anti-Inflammatory Mechanism of Insulin in Diabetes

Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis

Disregulated expression of co-stimulatory molecules PD-1 and CD28 on peripheral T lymphocytes in patients with acute coronary syndrome

Dendritic cell-mediated chronic low-grade inflammation is regulated by the RAGE-TLR4-PKCβ1 signaling pathway in diabetic atherosclerosis

PD-1/PD-L1 in cardiovascular disease

CD161+CD127+CD8+ T Cell Subsets Can Predict the Efficacy of Anti-Pd-1 Immunotherapy in Non-Small Cell Lung Cancer with Diabetes Mellitus

Pd-1 And Tim-3 Pathways Regulate Cd8(+) T Cells Function In Atherosclerosis

TGF-β1 induces PD-1 expression in macrophages through SMAD3/STAT3 cooperative signaling in chronic inflammation

PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression

Macrophages regulate plaque progression in diabetic Apoe-/- mice dependent on Pi4p/Nlrp3 signaling pathway

High-density Lipoprotein of Patients with Type 2 Diabetes Mellitus Upregulates Cyclooxgenase-2 Expression and Prostacyclin I-2 Release in Endothelial Cells: Relationship with HDL-associated Sphingosine-1-phosphate

The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients

Exploration of cross-talk and pyroptosis-related gene signatures and molecular mechanisms between periodontitis and diabetes mellitus via peripheral blood mononuclear cell microarray data analysis

The Combined Effect of Systemic Immune-Inflammation Index and Type 2 Diabetes Mellitus on the Prognosis of Patients Undergoing Percutaneous Coronary Intervention: A Large-Scale Cohort Study

CD8+ T and NK cells characterized by upregulation of NPEPPS and ABHD17A are associated with the co-occurrence of type 2 diabetes and coronary artery disease

Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes

Type 2 diabetes microenvironment promotes the development of Parkinson's disease by activating microglial cell inflammation

PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients

Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity

PD-L1 expression on peripheral T-cells and association with coronary heart disease patients: A protocol for systematic reviews and meta-analysis